Accelerates development timelines with faster, easier selection and scale up of clones.
Merck's CHOZN expression system will be used by SystImmune, a Seattle-based biotechnology company, for commercial development of a bi-specific antibody therapeutic.
The CHOZN expression system is designed to deliver manufacturing-ready robust and stable producing clones with a workflow that minimizes the resources needed to complete a cell line development project. As a result, users are able to quickly evaluate more molecules in their pipeline.
"When compared with alternate expression systems, our CHOZN system offers a turnkey solution that consistently delivers shortened development timelines," said Udit Batra, Member of the Merck Executive Board and CEO, Life Science.
Merck's CHOZN expression system is based on a GS -/- Chinese hamster ovary (CHO) cell line.
"With only two scientists in our cell science department, we were able to generate more than 10 stable cell lines using this platformin a single year," said Camilla Wang, Scientist, SystImmune. "The CHOZN platform outperformed other systems in many ways. It is easy to use, requires less time to generate final single cell clones, and most of all, the expression level is consistently higher compared to the other approaches."
Along with the CHOZN cells, Merck provides an expression vector, extensive user protocols, a comprehensive cell line history document and paired cGMP media and feeds.Services are offered for cell line development in the CHOZN expression system. Merck also offers gene engineering services using its CompoZr zinc finger nuclease technology to engineer CHO cell lines with characteristics attractive to biopharmaceutical developers and manufacturers, including resistance to Centinel technology.Read More
LifeArc negotiates exclusive licence deal with Nemysis for oral iron supplement technology20 Jul 2017
Catalent and academia on quest to better understand pediatric drug formulation and delivery challenges20 Jul 2017
Recipharm and LIDDS establish industrial manufacturing capabilities for a novel prostate cancer product20 Jul 2017